Following on from our submission last year to the Discussion Paper, Research Australia has welcomed the acknowledgment of the importance of research in the new draft National Medicines Policy (NMP). Research Australia has used our submission to highlight further areas under the policy’s pillars where research can play a critical role, and has called for a dedicated stream of funding for research to support the Policy’s implementation and objectives.
Research Australia believes the Governance and Implementation sections of the draft policy need more work and has joined with the medicines sector and consumer groups to call for further consultation before the NMP is finalised. The Government has now heeded this call, with the Minister for Health announcing on 23 March that there would be further consultation before the Policy is finalised.
Read Research Australia’s submission here.
The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 (the Bill) is part of the Government’s response to the recommendations of the review of Medicines and Medical Devices Regulation (MMDR), and the legislation is supported by Research Australia’s submission to the inquiry by the Senate Standing Committees on Community Affairs.
The aim of the Review’s recommendations is to improve the processes for the approval of medicines and medical devices by the Therapeutic Goods Administration. Together the regulatory reforms are expected to reduce the administrative burden on applicants and make the approval process faster without jeopardising the safety of consumers.
Achieving this aim will provide consumers with earlier access to potentially lifesaving new medicines and devices. It is also an effective means of supporting Australia’s medical device and medicines industries; by accelerating their pathway to market it will enable them to become profitable more quickly, providing them with more resources to pursue the international markets needed to be truly successful and profitable.
Research Australia submission TGA Bill
Research Australia has responded to the Victorian Governments’ discussion paper on the Victorian medical technologies and pharmaceuticals sectors, proposing the Victoria capitalise on its existing expertise in health and medical research and significant infrastructure to take advantage of future growth in this sector. There is significant scope of the Victorian Government to complement and take advantage of the Australian Government’s focus on the sector as a priority area for investment.
Victorian Medical Technology and Pharmaceuticals Strategy